Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer: Past, Present, and Hope for the Future
Keunchil Park
Cancer Res Treat. 2003;35(4):279-280.   Published online 2003 Aug 31     DOI:
Citations to this article as recorded by Crossref logo
Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer
Xin Wang, Jun Zhao, Lu Yang, Li Mao, Tongtong An, Hua Bai, Shuhang Wang, Xuyi Liu, Guoshuang Feng, Jie Wang
Medical Oncology.2010; 27(2): 484.     CrossRef
Clinical Significance of Vascular Endothelial Growth Factors (VEGF)-C and -D in Resected Non-Small Cell Lung Cancer
Yoon Ho Ko, Chan-Kwon Jung, Myung-Ah Lee, Jae Ho Byun, Jin Hyoung Kang, Kyo Young Lee, Keon Hyun Jo, Young Pil Wang, Young Seon Hong
Cancer Research and Treatment.2008; 40(3): 133.     CrossRef
Gefitinib (ZD1839): Therapy in selected patients with non-small cell lung cancer (NSCLC)?
Diego Dongiovanni, Lorenzo Daniele, Carla Barone, Vincenzo Dongiovanni, Camilla Fissore, Anna Sapino, Luigia Macrì, Giovanni Bussolati, Lucio Buffoni, Fabio Gaspari, Raffaella Grillo, Nadia Birocco, Alfredo Addeo, Libero Ciuffreda, Marina Schena
Lung Cancer.2008; 61(1): 73.     CrossRef
Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer
Jinny Park, Byung Bae Park, Jee Youn Kim, Se-Hoon Lee, Soon Il Lee, Ho Young Kim, Jung Han Kim, Se Hoon Park, Kyung-Eun Lee, Joon Oh Park, Kihyun Kim, Chul Won Jung, Young Suk Park, Young-Hyuck Im, Won Ki Kang, Mark H. Lee, Keunchil Park
Clinical Cancer Research.2004; 10(13): 4383.     CrossRef